News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
573,062 Results
Type
Article (47983)
Company Profile (92)
Press Release (524973)
Multimedia
Podcasts (196)
Webinars (27)
Section
Business (169924)
Career Advice (2443)
Deals (28510)
Drug Delivery (209)
Drug Development (69397)
Employer Resources (161)
FDA (16298)
Job Trends (12172)
News (268179)
Policy (30036)
Tag
2027 BioCapital Standard (4)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (7)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (10)
40 Under 40 (1)
Academia (2390)
Academic (1)
Accelerated approval (70)
ADA (44)
Adcomms (44)
Allergies (200)
Alliances (36479)
ALS (247)
Alzheimer's disease (1968)
Antibody-drug conjugate (ADC) (598)
Approvals (16738)
Artificial intelligence (831)
ASCO (305)
Autoimmune disease (427)
Automation (62)
Bankruptcy (318)
Belgium (17)
Best Places to Work (9211)
BIO (65)
Biologics (39)
BIOSECURE Act (23)
Biosimilars (271)
BioSpace Insights (161)
Biotechnology (56)
Bispecific (12)
Bladder cancer (221)
Brain cancer (85)
Breast cancer (799)
Cancer (6662)
Cardiovascular disease (593)
Career advice (2104)
Career pathing (58)
CAR-T (354)
CDC (79)
CDMO (184)
Celiac Disease (4)
Cell-line development (2)
Cell therapy (1008)
Cervical cancer (55)
Clinical research (62132)
Collaboration (2156)
Commercialization (30)
Company closure (9)
Compensation (1773)
Complete response letters (123)
COVID-19 (2791)
CRISPR (126)
CRO (1)
C-suite (1393)
Cystic fibrosis (165)
Data (9197)
Decentralized trials (4)
Denatured (48)
Depression (209)
Dermatology (159)
Diabetes (709)
Diagnostics (6023)
Digital health (55)
Diversity (8)
Diversity, equity & inclusion (43)
Drug discovery (393)
Drug pricing (246)
Drug shortages (34)
Duchenne muscular dystrophy (359)
Earnings (65649)
Editorial (85)
Employer branding (21)
Employer resources (148)
Events (86622)
Executive appointments (1140)
Eye disease (9)
FDA (20902)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (1)
Friedreich's ataxia (25)
Frontotemporal dementia (35)
Funding (1836)
Gene editing (266)
Generative AI (75)
Gene therapy (832)
GLP-1 (1265)
Government (4338)
Grass and pollen (8)
Guidances (418)
Healthcare (15270)
Hematology (173)
HIV (106)
Huntington's disease (78)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (137)
Immunology and inflammation (397)
Immuno-oncology (120)
Indications (239)
Infectious disease (3170)
Inflammatory bowel disease (227)
Inflation Reduction Act (14)
Influenza (139)
Intellectual property (340)
Interviews (467)
IPO (14245)
IRA (58)
Job creations (3193)
Job search strategy (1688)
JPM (69)
Kidney cancer (28)
Kidney disease (111)
Labor market (126)
Layoffs (673)
Leadership (65)
Legal (7049)
Licensing (43)
Liver cancer (108)
Longevity (40)
Lung cancer (911)
Lung diease (17)
Lymphoma (495)
Machine learning (68)
Management (56)
Manufacturing (1285)
Marketing (18)
MASH (231)
Medical affairs (3)
Medical device (11944)
Medtech (12179)
Mergers & acquisitions (15593)
Metabolic disorders (1872)
mRNA (288)
Multiple sclerosis (202)
Multispecific (3)
NASH (23)
Netherlands (17)
Neurodegenerative disease (540)
Neuropsychiatric disorders (142)
Neuroscience (3818)
Neurotech (3)
NextGen: Class of 2026 (5018)
Non-profit (3236)
Now hiring (43)
Obesity (916)
Opinion (336)
Ovarian cancer (246)
Pain (283)
Pancreatic cancer (395)
Parkinson's disease (433)
Partnered (34)
Patents (712)
Patient recruitment (865)
Patient selection (45)
Peanut (69)
People (45977)
Peptides (18)
Pharmaceutical (27)
Pharmacy benefit managers (40)
Phase 1 (18615)
Phase 2 (26915)
Phase 3 (22008)
Pipeline (11876)
Policy (407)
Postmarket research (2222)
Preclinical (7535)
Press Release (32)
Prostate cancer (370)
Psychedelics (90)
Radioligand (2)
Radiopharmaceuticals (350)
Rare diseases (1426)
Real estate (4354)
Recruiting (67)
Regenerative medicine (12)
Regulatory (25517)
Reports (56)
Research institute (2185)
Resumes & cover letters (408)
Rett syndrome (54)
RNA editing (30)
RSV (87)
Schizophrenia (207)
Series A (320)
Series B (239)
Service/supplier (7)
Sickle cell disease (129)
Special edition (33)
Spinal muscular atrophy (163)
Sponsored (56)
Startups (2859)
State (1)
Stem cells (1)
Stomach cancer (22)
Substance use disorders (21)
Supply chain (144)
Switzerland (1)
Tariffs (105)
The Weekly (146)
Vaccines (1292)
Venture capital (160)
Weight loss (629)
Wet AMD (5)
Women's health (146)
Worklife (27)
Date
Today (121)
Last 7 days (624)
Last 30 days (2497)
Last 365 days (29095)
2026 (22455)
2025 (28425)
2024 (31434)
2023 (35080)
2022 (45183)
2021 (48625)
2020 (45615)
2019 (36309)
2018 (27464)
2017 (27945)
2016 (25936)
2015 (28124)
2014 (21938)
2013 (17918)
2012 (19082)
2011 (19544)
2010 (17650)
Location
Africa (707)
Alabama (86)
Alaska (6)
Arizona (336)
Arkansas (13)
Asia (33480)
Australia (5919)
California (14561)
Canada (3384)
China (1426)
Colorado (574)
Connecticut (650)
Delaware (443)
Europe (83472)
Florida (2267)
Georgia (447)
Hawaii (5)
Idaho (41)
Illinois (1125)
India (109)
Indiana (585)
Iowa (29)
Japan (676)
Kansas (122)
Kentucky (46)
Louisiana (41)
Maine (83)
Maryland (1731)
Massachusetts (10449)
Michigan (329)
Minnesota (753)
Mississippi (5)
Missouri (151)
Montana (13)
Nebraska (24)
Nevada (158)
New Hampshire (64)
New Jersey (3857)
New Mexico (19)
New York (3745)
North Carolina (1810)
North Dakota (9)
Northern California (7581)
Ohio (418)
Oklahoma (22)
Oregon (37)
Pennsylvania (2665)
Puerto Rico (28)
Rhode Island (34)
South America (1060)
South Carolina (92)
South Dakota (2)
Southern California (5785)
Tennessee (227)
Texas (2306)
United States (50439)
Utah (364)
Vermont (1)
Virginia (359)
Washington D.C. (74)
Washington State (1121)
West Virginia (4)
Wisconsin (152)
Wyoming (3)
573,062 Results for "s vyn".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
July 3, 2025
·
7 min read
Press Releases
VYNE Therapeutics Provides Update on VYN202 Program
April 28, 2025
·
4 min read
Drug Development
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first healthy volunteers have been dosed in the Phase 1a trial of VYN202.
June 13, 2024
·
5 min read
Drug Development
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
VYNE Therapeutics Inc. today announced that the first subject has been dosed in a Phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo.
June 5, 2024
·
5 min read
Pharm Country
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the clearance of its Investigational New Drug application (“IND”) by the U.S. Food and Drug Administration for VYN202, an oral BD2-selective BET inhibitor.
May 6, 2024
·
5 min read
Pharm Country
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.
May 1, 2024
·
6 min read
Press Releases
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
February 20, 2025
·
6 min read
Press Releases
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
January 6, 2025
·
6 min read
Drug Development
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics Inc. today announced new preclinical data showing the positive effect of its oral small molecule BD2-selective BET inhibitor, VYN202, in preclinical models of psoriasis and rheumatoid arthritis.
October 30, 2023
·
8 min read
Drug Development
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
VYNE Therapeutics Inc. today announced new biomarker data from the previously completed Phase 1b trial in patients with nonsegmental vitiligo. The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.
January 10, 2024
·
8 min read
1 of 57,307
Next
